Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC7452 | 17-PA |
| Selective antagonist of neurosteroid potentiation and direct gating of GABAA receptors. Selectively reduces the effects of 5α-reduced steroids compared to 5β-reduced steroids and displays no effect on potentiation evoked by barbiturates and benzodiazepines. Attenuates 3α,5α-THP-induced loss of righting reflex and total sleep time following i.c.v administration in rats. | |
| BCC7454 | POM 1 |
| Inhibitor of Ecto-NTPDases that displays minor selectivity for NTPDases 1 and 2 over NTPDase 3 and P2Y12 (Ki values are 2.58, 3.26, > 10 and 28.8 μM for NTPDase 1, NTPDase 3, P2Y12 and NTPDase 2 respectively). Abolishes renal protection induced by ischemic preconditioning. Inhibits synaptic transmission at hippocampal CA1 pyramidal synapses and at the cerebellar parallel fiber-Purkinje cell (PF) synapse. | |
| BCC7457 | Cilastatin sodium |
| Dipeptidase inhibitor (LTDase, leukotriene D4 hydrolase, dehydropeptidase I) that displays a Ki value of 0.11 μM. Inhibits metabolism of LTD4 to LTE4 and the hydrolysis of β-lactam antibiotics. Nephroprotective; reduces toxic accumulation of cyclosporin A in kidney proximal tubule epithelial cells. | |
| BCC7458 | OGT 2115 |
| Heparanase inhibitor (IC50 = 0.4 μM) that displays no major inhibition of human cytochrome P450 isoenzymes (IC50 > 30 μM). Exhibits antiangiogenic properties in vitro (IC50 = 1 μM). | |
| BCC7465 | U 90042 |
| GABAA receptor ligand that binds with comparable affinities to three receptor subtypes: α1β2γ2, α3β2γ2 and α6β2γ2 (Ki values are 7.8, 9.5 and 11.0 nM respectively). Potentiates GABA-induced chloride currents in α6β2γ2 receptors. Sedative/hypnotic compound. | |
| BCC7466 | U 89843A |
| Positive allosteric modulator of GABAA receptors. Enhances GABA-induced Cl- currents in the α1β2γ2, α3β2γ2 and α6β2γ2 subtypes. Causes sedation in vivo following i.v. administration without losing "righting reflex". Also displays antioxidant activity. | |
| BCC7467 | PNU 96415E |
| Antipsychotic agent. Displays high affinity for dopamine D4 and serotonergic 5-HT2A receptors and relatively weak affinity at D2 receptors (Ki values are 3.0, 5.8, 134, 181, 199, 240, 411 and > 678 nM for D4, 5-HT2A, 5-HT1A, α1, D2, D3, D1, α2 and muscarinic receptors respectively). Inhibits exploratory locomotor activity and antagonizes d-amphetamine-induced locomotor stimulation in rats. | |
| BCC7468 | Sazetidine A dihydrochloride |
| Subtype-selective α4β2 nicotinic acetylcholine receptor ligand (Ki values are 0.26 and 54 nM at α4β2 and α3β4 receptors respectively). May act as a silent desensitizer or as an agonist, depending on subunit stoichiometry (EC50 = 1.1 nM for nAChR-stimulated dopamine release). Exhibits analgesic activity in vivo and significantly reduces nicotine self-administration in an experimental rat model. | |
